By Charles Bankhead
Olaparib-bevacizumab maintenance boosts PARP inhibitor benefits beyond BRCA-mutated subgroup.
Dual maintenance therapy with olaparib (Lynparza) and bevacizumab (Avastin) significantly improved progression-free survival (PFS) in women with newly diagnosed advanced ovarian cancer, as compared with single-agent bevacizumab, a … Read more
By Dave Levitan
The combination of niraparib and bevacizumab significantly improved progression-free survival compared with niraparib alone in a phase II study of patients with platinum-sensitive recurrent ovarian cancer. The chemotherapy-free regimen will now be tested in a phase III … Read more
Although the number of women being diagnosed and dying of ovarian cancer is declining, recurrence, drug resistance, and mortality remains high for women with high-grade serous ovarian carcinoma, the most common form of epithelial ovarian cancer.
A new study in … Read more
By Thomas J. Pier, MSW, LCSW, OSW-C, CMF, and Marina Baroff, MPH, MA, FACHE
What if every woman with ovarian cancer had help setting a clear direction through the uncertain landscape of the diagnosis? Imagine these women having access to … Read more
By Peter MacCallum
An international study led by Peter Mac has revealed the origin of mucinous ovarian cancer (MOC) confirming, unlike other types of ovarian cancer, this rare cancer is not seeded from elsewhere in the body.
The research provides … Read more
By Dr. Laura Shawver, Founder of The Clearity Foundation
Whenever I talk with someone who just received an ovarian cancer diagnosis, it brings back the feelings that I had when I heard the words, “you have ovarian cancer.” I can … Read more
By Dave Levitan
The combination of a poly (ADP-ribose) polymerase (PARP) inhibitor and immune checkpoint inhibition with tislelizumab was well tolerated and showed promising anti-tumor activity in a phase I trial of patients with multiple solid tumor types, according to … Read more
Researchers from Queen’s University Belfast have developed a test that may be able to detect ovarian cancer up to two years earlier than current approaches.
The researchers discovered that the presence of four proteins together, known as a biomarker panel, … Read more
This article discusses the anxiety that often surrounds a cancer diagnosis and the importance of seeking professional help. Steps Through OC offers free, professional ovarian cancer counseling for women, families and caregivers coping with ovarian cancer. Our goal is to … Read more
By John Lauerman
AstraZeneca Plc’s Lynparza got a boost from results of a study that may widen the drug’s use among patients with advanced ovarian cancer.
Ovarian tumor growth slowed in patients who got Lynparza in addition to a … Read more
By Michael J. Birrer, MD, PhD
There will be 22,530 new cases of ovarian cancer in the United States this year.
Although tumors often present at an advanced stage, it remains one of the most chemosensitive epithelial cancers, with a … Read more
By Kristen Monaco
Researchers advocate for increased hormone therapy for high-risk women.
Bone health suffered in women with a BRCA mutation who underwent preventive oophorectomy, Canadian researchers reported.
Premenopausal women with the BRCA1 or BRCA2 mutation experienced a significant decline … Read more
By Sherry B. Hanson
While recovering from ovarian cancer and chemotherapy, I got it into my head that I needed a garden space. My garden represents not only my physical labor, but also my focus, which is on the future.… Read more
By Leah Lawrence
In addition to putting carriers at increased risk for breast and ovarian cancers, BRCA2 germline mutations carriers are also at increased risk for pediatric and adolescent non-Hodgkin lymphoma (NHL), according to data from the SJLIFE study.… Read more
By Alexandru Micu
Stanford University (SU) researchers have found a new signaling molecule that cancer cells use to keep the immune system at bay.
Our bodies’ immune cells are, among other objectives, tasked with clearing out malfunctioning cells. In theory, … Read more
By Amirah Al Idrus
PARP inhibitors have transformed treatment for breast and ovarian cancers, but their use has been limited to the small proportion of patients who have BRCA mutations. New research out of UT Southwestern Medical Center has uncovered … Read more
By Dave Levitan
A phase II study found that the combination of ribociclib and letrozole showed promising activity in patients with estrogen receptor-positive ovarian cancer and endometrial cancer. The most benefit was observed in low-grade serous ovarian cancers.
“Up to … Read more
This article shares wonderful advice on how to support a loved one with cancer, but there are times when their families and caregivers need that support, too. Steps Through OC offers free, professional ovarian cancer counseling for women, families and
… Read moreBy Zachary Sweger
Preventing a protein from doing its job may keep a certain type of ovarian cancer cell from growing and dividing uncontrollably in the lab, according to a new study from Penn State College of Medicine.
In … Read more
By Jack Elliot
In June 2019, the FDA announced a new program called “Project Facilitate” that is designed exclusively for patients with advanced cancer who have exhausted all available treatment options and are unable to participate in clinical trials. Through … Read more
